Knowledge Intensive Services
The Paradigm Shift: Navigating the emergence of value-based contracts for future gene therapies
Value-based contracting (VBC) has been difficult to execute in the pharmaceutical arena, especially in the gene therapy space. This has been driven by several factors, including the lack of long-term data, the imbalance of upside and downside risk between manufacturers and payers, and d...
Making AI work for you: 6 tips to future-proof your career
Career Ambitions writes...How do you feel about the rapid development in AI? Fascinated? Terrified? Maybe a little bit of both? Whilst the possibilities it offers are undoubtedly exciting, the alarming predictions in the media about how AI could kill certain jobs, has left many of us f...
Meeting digital and technology standards, as well as cyber security standards in schools
Breathe Technology writes… even though it’s almost Christmas!
Strategies for combination therapy in oncology: Part one – Business as usual
This is the first in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In this article, we discuss the challenges and opportunities within the current landscape and key issues impacting pricing and access for comb...
Strategies for combination therapy in oncology: Part two - Working with the “status quo”
This is the second article in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In this article, we investigate strategies that manufacturers could consider to optimize pricing and access opportunities for their c...
Antimicrobial Resistance Policy Solutions
It is difficult to imagine someone who hasn’t called on antibiotics to help them through an infection or protect them during a surgery. Thanks to developments over the last 150 years, once life-threatening bacterial encounters have been relegated to minor inconveniences. Or have they? T...
Good business coaching is so powerful that if it were a drug it would be illegal
Chris Dunn writes..It’s use it or lose it time! But don't just spend your end-of-year budget, invest it for maximum return. And there's no better return than investing in executive coaching or business mentoring. ...
How well equipped are you to lead change?
Chris Dunn writes...Leading change is one of the most challenging aspects of leadership. This is not only because the pace of change is accelerating but also because so much seems to be changing all at the same time. So, where do leaders and senior managers get the right support to hel...
3 Steps for cell & gene therapy medical affairs teams to provide strategic value
A phrase often recited within the pharmaceutical and biotechnology industries in recent years is that medical affairs is the third strategic pillar of success, along with R&D and commercial. Ongoing advancements in the cell and gene therapy sector have further highlighted the critic...
The Paradigm Shift: Navigating the emergence of value-based contracts for future gene therapies
Value-based contracting (VBC) has been difficult to execute in the pharmaceutical arena, especially in the gene therapy space. This has been driven by several factors, including the lack of long-term data, the imbalance of upside and downside risk between manufacturers and payers, and d...